Market Update Graphic
Source: The Market Online
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Christmas is fast approaching and the ASX200 has been down 0.35% at 8,267 points. The Santa rally has so far failed to materialise as the latest round of Chinese stimulus underwhelmed investors.

The Iron Ore price is steady at around US$103.75 per tonne in Singapore after sliding on the weekend.

Materials has been the poorest performing sector, down 1.6%, followed by IT and Real Estate, both down around 0.65%.

Utilities has been the best, up 0.3%, followed by Industrials and Financials, up 0.2%.

Company News

Online retailer Kogan (ASX:KGN) has been down 1% on the news ASIC is investigating a potentially controversial options deal involving two of its senior executives, including founder Ruslan Kogan. The deal netted $17 million in profits for the executives and the company is cooperating with the investigation.

Kogan has been $5.60.

Fortescue (ASX:FMG) has been down 2.4% as analysts at Bell Potter retain their Sell rating saying it’s ‘hard to see the upside.’ The broker notes certain high-grade ores which are more carbon efficient may encounter specific tailwinds in the new year.

Fortescue has been $18.81.

Invex Therapeutics (ASX:IXC) has had success simulating the use of Exenatide to improve cell survival in a 3D ‘human brain model’ of Alzheimer’s disease.

Invex Therapeutics has been 7.4 cents.

More From The Market Online
Market Close Graphic

ASX Market Close: Another reversal as just-green Oz markets ignore US dive | Jan 3, 2024

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next